Insider Transactions in Q2 2021 at Hca Healthcare, Inc. (HCA)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2021
|
Jon M Foster EVP and COO |
BUY
Bona fide gift
|
Indirect |
4,919
+9.13%
|
-
|
|
May 13
2021
|
Jon M Foster EVP and COO |
SELL
Bona fide gift
|
Indirect |
4,919
-100.0%
|
-
|
|
May 12
2021
|
Jon M Foster EVP and COO |
BUY
Bona fide gift
|
Indirect |
9,838
+29.57%
|
-
|
|
May 12
2021
|
Jon M Foster EVP and COO |
SELL
Bona fide gift
|
Direct |
9,838
-75.0%
|
-
|
|
May 11
2021
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Open market or private sale
|
Direct |
3,432
-34.29%
|
$713,856
$208.33 P/Share
|
|
May 06
2021
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
7,672
-37.33%
|
$1,588,104
$207.55 P/Share
|
|
May 05
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
40,626
-44.8%
|
$8,409,582
$207.19 P/Share
|
|
May 04
2021
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,328
-35.54%
|
$2,333,568
$206.34 P/Share
|
|
May 04
2021
|
P. Martin Paslick SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+37.34%
|
$1,292,000
$68.96 P/Share
|
|
May 04
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
19,043
-17.35%
|
$3,903,815
$205.3 P/Share
|
|
May 04
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Open market or private sale
|
Direct |
4,604
-14.23%
|
$939,216
$204.0 P/Share
|
|
May 03
2021
|
A Bruce Moore Jr Group President - Service Line |
SELL
Open market or private sale
|
Direct |
12,000
-10.49%
|
$2,460,000
$205.32 P/Share
|
|
May 03
2021
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
2,417
-12.51%
|
$493,068
$204.32 P/Share
|
|
May 03
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
21,584
-16.44%
|
$4,424,720
$205.21 P/Share
|
|
Apr 30
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Bona fide gift
|
Indirect |
46,890
+39.71%
|
-
|
|
Apr 30
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Bona fide gift
|
Indirect |
23,445
-100.0%
|
-
|
|
Apr 30
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Bona fide gift
|
Direct |
23,445
-91.83%
|
-
|
|
Apr 30
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
7,396
-18.61%
|
$1,486,596
$201.06 P/Share
|
|
Apr 30
2021
|
Christopher F. Wyatt SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+13.97%
|
$888,000
$74.69 P/Share
|
|
Apr 30
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,843
-1.38%
|
$374,129
$203.06 P/Share
|
|
Apr 29
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
18,664
-47.82%
|
$3,751,464
$201.53 P/Share
|
|
Apr 29
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,794
-8.86%
|
$762,594
$201.94 P/Share
|
|
Apr 29
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,930
+12.16%
|
$480,330
$81.96 P/Share
|
|
Apr 29
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
72,846
-10.05%
|
$14,642,046
$201.56 P/Share
|
|
Apr 28
2021
|
Meg Crofton Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+17.49%
|
-
|
|
Apr 28
2021
|
Robert J Dennis Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+3.74%
|
-
|
|
Apr 28
2021
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+4.53%
|
-
|
|
Apr 28
2021
|
Thomas F Frist Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,938
+17.85%
|
-
|
|
Apr 28
2021
|
William R Frist Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,435
+14.49%
|
-
|
|
Apr 28
2021
|
Charles O Holliday Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+4.65%
|
-
|
|
Apr 28
2021
|
Michael W Michelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,435
+17.48%
|
-
|
|
Apr 28
2021
|
Wayne Joseph Riley Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+7.0%
|
-
|
|
Apr 28
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
72,845
-9.41%
|
$14,496,155
$199.51 P/Share
|
|
Apr 27
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Open market or private sale
|
Direct |
38,390
-60.08%
|
$7,639,610
$199.91 P/Share
|
|
Apr 27
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Open market or private sale
|
Indirect |
25,000
-100.0%
|
$5,000,000
$200.08 P/Share
|
|
Apr 27
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Bona fide gift
|
Indirect |
50,000
+50.0%
|
-
|
|
Apr 27
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Bona fide gift
|
Direct |
25,000
-28.12%
|
-
|
|
Apr 27
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Bona fide gift
|
Direct |
25,000
+21.95%
|
-
|
|
Apr 27
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Bona fide gift
|
Indirect |
50,000
-71.63%
|
-
|
|
Apr 23
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Open market or private sale
|
Direct |
37,305
-36.86%
|
$7,461,000
$200.03 P/Share
|
|
Apr 23
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
74,065
-42.26%
|
$14,961,130
$202.5 P/Share
|
|
Apr 23
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
112,455
+12.76%
|
$11,245,500
$100.99 P/Share
|
|
Apr 20
2021
|
Jon M Foster EVP and COO |
SELL
Open market or private sale
|
Direct |
5,504
-35.88%
|
$1,067,776
$194.9 P/Share
|
|
Apr 16
2021
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,496
-29.75%
|
$1,273,216
$196.93 P/Share
|
|
Apr 16
2021
|
Jon M Foster EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+35.46%
|
$564,000
$47.97 P/Share
|